Pharmaceuticals, Biotechnology and Life Sciences
Faron Pharmaceuticals Oy (Faron), the clinical stage biopharmaceutical company, has started dealing its Ordinary Shares on the AIM market of the London Stock Exchange with effect from 8.00 a.m. Tuesday after placing and subscription for 3,846,154 new Ordinary Shares, raising £10.0 million at a price of 260p per ordinary.
Amgen will present eight IMLYGIC (talimogene laherparepvec) abstracts, including data from the Phase 3 trial and new data from its Phase 1b combination trial with Merck’s anti-PD-1 therapy, at the 12th International Congress of the Society for Melanoma Research …
Gilead Sciences, Inc. said Monday that its Phase 3 Study 115 evaluating Zydelig (idelalisib) added to standard therapy in previously-treated chronic lymphocytic leukemia (CLL) patients will be unblinded early.
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) injection for intravenous infusion for the treatment of patients with multiple myeloma
A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy.
The OSIRIS trial Phase II a investigating once daily OLYSIO (simeprevir) in combination with sofosbuvir in hepatitis C virus (HCV) genotype 4 infected patients, with and without liver cirrhosis, demonstrated treatment to be safe.
A Roche drug that can prolong the lives of some women with advanced breast cancer has been plunged back into the centre of a drug pricing row after Britain’s health cost agency declared that it is still too expensive.
A single dose of Bimatoprost Sustained-Release (SR) lowered intraocular pressure (IOP) in 92 percent (n= 69) of glaucoma patients at 4 months and 71 percent (n=53) at 6 months while demonstrating a favorable efficacy and safety profile.
The National Health Service (NHS) in England has more than doubled funding from £15m to £31m for its clinical pharmacists in general practice pilot, due to an overwhelmingly positive response from GP surgeries.
LEO Pharma and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million.